Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Giuliana Muti(Ospedale Maggiore), Enrica Morra(San Antonio College), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Fausto Baldanti(University of Pavia), Patrizia Comoli(Policlinico San Matteo Fondazione), Catherine Klersy(Policlinico San Matteo Fondazione), Silvia Cantoni(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Annamaria Nosari(Unknown), Valentina Rossi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Giovanna D’Avanzo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Pierluigi Oreste(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Guido Gini(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
PubMed
January 1, 2002
Cited by 82
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|PubMed|2006|909
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907